INTERNATIONAL PATENT: BREAKPOINT THERAPEUTICS GMBH FILES APPLICATION FOR "QUINAZOLINE DERIVATIVES SUITABLE FOR USE AS WERNER SYNDROME HELICASE PROTEIN INHIBITORS"

GENEVA, Dec. 29 -- BREAKPOINT THERAPEUTICS GMBH (Essener Bogen 722419 Hamburg) filed a patent application (PCT/EP2025/067216) for "QUINAZOLINE DERIVATIVES SUITABLE FOR USE AS WERNER SYNDROME HELICASE PROTEIN INHIBITORS" on Jun 18, 2025. With publication no. WO/2025/262192, the details related to the patent application was published on Dec 26, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): BENTLEY, Jonathan (c/o Evotec (UK) LtdDorothy Crowfoot Hodgkin Campus114 Innovation DriveMilton ParkAbingdon Oxfordshire OX14 4RZ), CAIRNS, Andrew (c/o Evotec (UK) LtdDorothy Crowfoot Hodgkin Campus114 Inn...